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METHODOLOGY Open Access
Development and validation of a novel
bioassay to determine glucocorticoid
sensitivity
Emily L. Williams1,2†, Madeleine L. Stimpson1,2†, Peter L. Collins1,3, Doyo G. Enki4, Ashish Sinha3,
Richard W. Lee1,2* and Ashwin D. Dhanda1,5,6
Abstract
Background: Glucocorticoids (GCs) remain the first line treatment for almost all non-infectious inflammatory
diseases, ranging from acute asthma to rheumatoid arthritis. However, across all conditions, patients have a variable
response to GCs with approximately 30% being non-responders. This group of GC resistant patients is typically
exposed to high-dose GCs and their side-effects before more appropriate immunotherapy is instituted. Hence, there
is a pressing clinical need for a predictive biomarker of GC responsiveness. The availability of such a tool would also
enable patient stratification for the conduct of smart clinical trials in GC resistance. Lymphocyte GC sensitivity has
been shown to be closely associated with clinical GC sensitivity in a number of inflammatory diseases. However,
the method for determining in vitro GC response is not standardized and requires the use of specialist equipment,
including a radioisotope to quantify cellular proliferation, making it challenging to translate into clinical practice.
Results: Here we describe the optimization and validation of a novel non-radioactive in vitro bioassay based on
measuring cellular proliferation by incorporation of bromodeoxyuridine (BrdU), termed the BrdU incorporation in
lymphocyte steroid sensitivity assay (BLISS). In comparison to the current gold standard lymphocyte GC sensitivity
assay in 101 healthy control samples, BLISS has an area under receiver operating characteristic of 0.82 and a
sensitivity of 83% for correctly identifying GC resistant subjects.
Conclusions: The performance of the novel BLISS bioassay makes it a strong candidate biomarker for clinical
application. It now requires validation in a prospective patient cohort.
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Background
For more than half a century glucocorticoids (GCs)
have formed the mainstay of the initial treatment of al-
most all non-infectious inflammatory diseases including
asthma, inflammatory bowel disease, rheumatoid arth-
ritis, non-infectious uveitis and acute severe alcoholic
hepatitis. However, response to GCs in patient popula-
tions is variable and in each disease group a cohort of
GC non-responders (approximately 30% of all patients)
has been clearly described [1–4]. GC resistant patients
are both at risk of the consequences of their uncon-
trolled disease and, because they require higher and
longer courses of therapy, they also incur a greater bur-
den of treatment side-effects. This could be avoided if
alternative immunotherapeutics were to be instituted
early in their disease course, but at present there is no
way of identifying GC resistant individuals prior to GC
treatment. Hence, there is an overt clinical need to de-
velop a biomarker of GC resistance prior to induction
of therapy as a tool for personalized healthcare.
GCs have wide ranging effects on many cells and tissues.
They bind to cytoplasmic GC receptors, which translocate
to the nucleus and bind to DNA at GC responsive elements
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resulting in transcriptional regulation by either transac-
tivation or transrepression of target genes, leading to
reduction in inflammation. The main mechanism of
GC anti-inflammatory action is through interference
with pro-inflammatory transcription factors such as nu-
clear factor kappa B and activator protein 1 [5]. Although
efficacious in many diseases, prolonged exposure to GCs
results in numerous undesirable side-effects including
osteoporosis, diabetes, infection and increased cardiovas-
cular risk [6, 7]. Therefore GCs should be used selectively
in responsive patients where a therapeutic benefit can
be achieved. Measurement of individual GC sensitivity
could therefore be crucial to permit appropriate strati-
fied treatment.
In patients with bronchial asthma it was demonstrated
that GC sensitivity correlated with in vitro lymphocyte
GC sensitivity rather than with a measure of disease
severity, decline in lung function [8, 9]. In these studies,
GC sensitivity was quantified in vitro by measuring the
inhibitory effect of dexamethasone (a synthetic GC) on
phytohaemagluttinin (PHA)-induced lymphocyte prolifer-
ation in peripheral blood mononuclear cells (PBMCs).
This assay, known as the Dexamethasone Inhibition of
Lymphocyte Proliferation Assay (DILPA), demonstrates a
wide range in GC sensitivity in healthy controls, which is
stable over time and not related to intrinsic cortisol pro-
duction [10]. Approximately 30% of the reported popula-
tion, and also in other healthy control populations, are
classified as GC resistant by DILPA [10, 11], which corre-
sponds to the overall proportion of GC resistant patients.
This suggests that the individual’s GC sensitivity is inher-
ent in the presence or absence of disease. When applied
to inflammatory diseases DILPA predicts clinical GC re-
sponse better than traditional measures of disease severity
in patients with ulcerative colitis [12, 13], alcoholic hepa-
titis [3, 14] and rheumatoid arthritis [15].
Traditionally, in order to quantify lymphocyte GC
sensitivity, cell proliferation is determined by labelling
dividing cells with tritiated thymidine (3H, a radioiso-
tope of hydrogen) and measuring the beta radiation
emission using a beta counter. This technique necessi-
tates expensive equipment that is not widely available
in many healthcare or commercial laboratories. Along-
side this, there are stringent health and safety standards
that can impede the use of radiation for many organiza-
tions. The clinical translation of this assay has therefore
been limited and currently only a few institutions are
performing the DILPA in a research setting.
There is consequently a requirement for an alternative
GC sensitivity assay which can be easily performed in
any laboratory setting. Therefore, the aim of this study
was to develop and validate a novel bioassay to measure
in vitro GC sensitivity. Bromodeoxyuridine (BrdU) is a
synthetic pyrimidine analogue of thymidine, which is
incorporated into the DNA of cells undergoing division
in the S phase of the cell cycle and can be detected using
labelled antibodies to BrdU by chemiluminescence, flow
cytometry or colorimetric assays. Therefore, detection of
newly synthesized DNA using BrdU can be used as an
indirect measure of cell proliferation [16–18]. Using a
commercially available colorimetric assay, which does
not require bespoke equipment or expertise, we have de-
veloped a novel measure of GC sensitivity termed the
BrdU Lymphocyte Incorporation Steroid Sensitivity
(BLISS) assay. In this report we describe the full assay
protocol and validation of the BLISS assay to measure
clinical GC sensitivity in comparison to the standard
DILPA.
Methods
This study was conducted under ethical approval from
the NHS Health Research Authority (reference: 04/
Q2002/84). After obtaining written informed consent
20 mL peripheral blood was taken from healthy subjects
by standard venepuncture into EDTA collection tubes.
PBMCs were isolated by density gradient centrifugation
over Ficoll-Paque Plus (VWR International, Lutterworth,
Leicestershire, UK) using Leucosep tubes (Greiner Bio-
One International, Stonehouse, Gloucestershire, UK)
and cell viability assessed by Trypan blue exclusion.
Cells were counted manually by light microscopy using
a hemocytometer.
DILPA
The DILPA was performed as previously described [3, 12].
In brief, 2 × 106 PBMCs / ml were suspended in RPMI
media (Thermo Fisher Scientific, Loughborough,
Leicestershire, UK) supplemented with 10% heat inacti-
vated fetal calf serum (Thermo Fisher Scientific),
2 mM L-glutamine (Thermo Fisher Scientific) and 100
U/mL penicillin and streptomycin (Thermo Fisher
Scientific). Cells were cultured in a 96-well plate in
triplicate with 20 μg/mL PHA (Sigma-Aldrich, Poole,
Dorset, UK) in the presence or absence of 1 × 10−6 M
Dexamethasone (Sigma-Aldrich, Poole, Dorset) for 42 h
at 37°C with 5% CO2. A saturating dose of 185 kBq/ml
3H was then added and cultured for a further 6 h. Con-
trol wells with unstimulated cells were also included.
The plate was harvested onto glass fibre filter paper
(Wallac Oy, Turku, Finland) using a cell harvester
(Skatron, Cox Scientific, Rothwell, Northamptonshire,
UK) and beta emission measured using a Micro β
emission scintillation counter (Wallac) in counts per
minute (cpm). Samples with cpm < 10,000 were consid-
ered a technical failure and excluded from analysis
(n = 6 in the optimization phase of experiments).
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BLISS assay
PBMCs were isolated and cultured for 42 h in triplicate as
described for the DILPA. Control wells of media alone,
BrdU reagent alone and anti-BrdU-peroxidase antibody
alone were also included in triplicate. BrdU reagent was
added for the final 6 h of culture at 10 μM. BrdU was then
detected using a commercial kit according to the manu-
facturer’s instructions (Roche Diagnostics, Burgess Hill,
UK). The protocol was optimized to determine the most
appropriate cell density, processing time and time of ex-
posure to the developing substrate. The final standardized
protocol is described fully in the results section.
Statistical analysis
For the standard DILPA and BLISS assay the maximum
percentage inhibition of proliferation (Imax) was calculated:
Imax ¼ 1 – proliferation in presence of GC½  =
proliferation in absence of GC½ 100
Although Imax values for both DILPA and BLISS give
a percentage suppression of proliferation by GCs, the
underlying assays use different methods with different
units and scales. Therefore, in order to place both assays
on a similar scale to compare the results more meaning-
fully, the BLISS dataset was first calibrated using an in-
verse regression model.
A Bland and Altman test of agreement was then per-
formed between DILPA and the adjusted BLISS and 95%
limits of agreement were determined [19].
To assess the accuracy of the adjusted BLISS Imax in
predicting DILPA Imax an area under receiver operating
characteristic (AUROC) was calculated and compared to
the diagonal reference line.
The previously determined threshold to define GC
sensitivity of Imax = 60% [10] was applied to the DILPA
dataset. The 60% threshold was adjusted according to
the inverse regression model and applied to the BLISS
dataset. Accuracy of the BLISS assay was compared to
the DILPA applying the adjusted threshold to produce
categorical data to give a contingency table.
Results
Subjects
Following optimization, 101 assays were performed on
samples from unique healthy individuals using the stan-
dardized BLISS assay technique as described below.
There were no DILPA values excluded from the final
analysis due to technical failure with low proliferation in
PHA stimulated wells < 10,000 cpm. For the BLISS assay
there was a single technical failure for sample with low
proliferation in the PHA stimulated wells which was not
included in the final analysis.
Standardized BLISS assay protocol
PBMCs were cultured at 2 × 106 / ml in triplicate in a 96-
well plate exactly as described for the standard DILPA
with 20 μg/ml PHA in the presence or absence of 1 × 10−6
M dexamethasone at 37°C with 5% CO2 for 42 h in a total
volume of 200 μL. Twenty microlitre per well BrdU label-
ling solution diluted 1:100 in RPMI supplemented with
10% FCS, L-glutamine and antibiotics (complete media)
were added to all experimental wells and to media alone
for a negative control and cultured for a further 6 h. Cells
were resuspended and the entire well volume transferred
directly to a 96-well flat bottomed plate and centrifuged
for 10 min at 300 g. Supernatants were aspirated and
discarded. The plate was dried for 1 h in a 60°C oven or
for 15 min using a standard hair drier. The dry plate
was covered and left overnight at 4°C. For more rapid
results this step can be omitted by proceeding directly
to fixing the cells and denaturing the DNA. Results are
similar if processed directly or after keeping at 4°C
overnight (Pearson’s r = 0.82 for 29 subjects). 200 μL / well
of FixDenat solution was added to fix and denature the
DNA and incubated for 30 min at room temperature.
FixDenat solution was removed by flicking off and tapping
plate. 100 μL / well anti-BrdU-peroxidase conjugate (pre-
diluted at 1:100 with antibody diluent solution) was added
to all experimental wells and to negative control wells.
The plate was incubated for 90 min at room temperature.
Antibody solution was removed by flicking off and tapping
plate. Plates were washed three times with 200 μL / well
of washing solution diluted 1:10 with distilled H2O. A final
wash was performed with 200 μL / well Phosphate Buff-
ered Saline (PBS). Wash solution was removed by flicking
off and tapping plate. 100 μL / well of substrate was added
and incubated for 5 min at room temperature. Absorb-
ance of the samples was measured in an ELISA plate
reader at 370 nm (reference wavelength 492 nm). Absorb-
ance (A370nm–A492nm) was calculated for each well. The
value for Imax was then also calculated as shown above.
BLISS and DILPA data have different distributions
The Imax values for both assays are approximately
normally distributed, confirming that there is a range
of GC sensitivity seen in the healthy population
(Fig. 1). However, the mean and standard deviations
(sd) for each test are significantly different: mean
DILPA is 48.2% (sd 26.3%) and mean BLISS is 32.5%
(sd 21.2%) (p < 0.001; unpaired t test).
BLISS assay accurately predicts GC resistance
Inverse regression provides the following model:
BLISS Imax ¼ 6:8 þ 0:53  DILPA Imaxð Þ
The BLISS dataset was then adjusted by using the
equation (BLISS Imax–6.8) / 0.53 and a Bland and
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Altman test of agreement was performed (Fig. 2). The
bias was found to be −0.2% with 95% limits of agree-
ment from −59.2 to 58.7%.
Using the adjusted BLISS dataset to predict DILPA,
AUROC was 0.82 (95% confidence interval [CI]: 0.73–0.92;
p < 0.001; Fig. 3).
Applying the inverse regression model to the prede-
fined threshold for GC sensitivity of 60% for DILPA
[12] gives a threshold of 38.7% for BLISS. Classifying
subjects as GC sensitive or GC resistant using the pre-
defined threshold for the DILPA and the adjusted
threshold for BLISS demonstrates that the BLISS assay
has 83% sensitivity (95% CI: 71–90%) and 69% specificity
(95% CI: 50–83%) compared to the DILPA (Table 1).
Discussion
Here we report the use of the novel BLISS assay to deter-
mine GC sensitivity. It has a suitably high AUROC (0.82)
and sensitivity in correctly identifying GC non-responders
(83%) in reference to the existing gold standard lymphocyte
Fig. 1 Distribution of Imax for DILPA a and BLISS assay b. Frequencies have been binned in 10% groups in 101 healthy control samples and the
normal distribution curve overlaid. The mean and standard deviation for DILPA is 48% and 26 and for BLISS 32% and 21, respectively. Their distributions
are significantly different (unpaired t-test p < 0.001)
Fig. 2 Bland and Altman test of agreement for DILPA and BLISS.
Bland and Altman plot of average versus difference for DILPA and
BLISS (adjusted by the inverse regression model of 6.8 + [5.3 ×
DILPA]). Bias (mean difference between DILPA and BLISS) is −0.2%
with 95% limits of agreement from −59.2 to 58.7% (dashed lines)
Fig. 3 BLISS has a high accuracy in predicting DILPA. Receiver
operating characteristic for BLISS (adjusted by inverse regression
model) in predicting DILPA with diagonal reference line (dashed).
AUROC= 0.82 (95% CI 0.73–0.92; p < 0.001 compared to reference line)
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GC sensitivity assessment method (DILPA). The sensi-
tivity of BLISS in identifying GC non-responders is the
most important measure of diagnostic accuracy; it must
correctly identify those patients who do not respond to
GCs so as to reliably reduce their unnecessary exposure
to GCs and guide alternative management. Secondly, it
is important to identify those who can benefit from GCs
so as not to inappropriately withhold GC treatment.
Therefore specificity of BLISS is of secondary importance
(69% in comparison to DILPA).
The simplicity of the assay, which uses a commer-
cially available kit and does not require complex equip-
ment or processing techniques, means it can be
performed in any laboratory that has cell culture facil-
ities. Unlike the DILPA, the BLISS assay does not have
any radiation safety concerns and does not require the
purchase and maintenance of expensive laboratory
equipment. The BLISS assay is also more reliable than
the DILPA. In 10 subjects who had DILPA and BLISS
repeated on a second occasion several weeks later, there
was poor correlation with their previous DILPA Imax
value (r = 0.45). The BLISS assay demonstrated closer
correlation (r = 0.59). In addition, there was also <1%
technical failure rate. These attributes make this an ap-
pealing assay to apply to patients with a range of in-
flammatory and autoimmune diseases with potential to
allow clinicians to stratify patient risk and develop
more individualized treatment programs.
We note that the Bland and Altman test of agreement
demonstrated wide 95% limits of agreement between the
DILPA and BLISS assays. This is likely to reflect the
variability of functional assays and particularly the meas-
urement of proliferation by 3H incorporation and beta
emission detection. However, the Bland and Altman test
of agreement is not an appropriate statistical measure
for comparison between the DILPA and BLISS since, al-
though readings are converted to the same units (Imax),
the underlying quantities differ (cpm and absorbance)
[20]. Therefore, regression together with AUROC ana-
lysis and a categorical comparison are more appropriate
to determine whether the BLISS assay is similar to the
DILPA in identifying GC resistant patients. Additionally,
in a cohort of healthy controls in the absence of disease
it is impossible to correlate either assay with clinical
phenotype and steroid responsiveness. Therefore the
BLISS assay now requires validation in a cohort of patients
with inflammatory diseases. Such validation is currently
underway in a cohort of patients with acute severe alco-
holic hepatitis, an inflammatory disease of the liver in
which GCs are the only treatment known to improve sur-
vival. Preliminary data from 10 patients demonstrate that
the BLISS assay significantly correlates with the current
gold standard measure of GC responsiveness known as
the Lille score with a correlation coefficient of −0.74 (p =
0.02; Additional file 1: Table S1) [21]. The Lille score is
calculated from clinical and biochemical parameters after
7 days of GC treatment with higher Lille scores associated
with greater GC resistance (hence the negative correlation
coefficient). This suggests that the BLISS assay has clinical
translatability which will be addressed after the adequately
powered study in 200 patients has been completed.
In this normal volunteer cohort we applied an adjusted
GC sensitivity threshold to the BLISS assay based on the
inverse regression model. However, this may not be ap-
propriate because there is a different distribution of BLISS
assay Imax with a lower mean and standard deviation than
the DILPA. Accurate determination of the best threshold
to define GC sensitivity is best achieved in a new cohort
of patients with clear clinical definitions of GC sensitivity
and resistance, which are independent of the assay.
In current clinical practice, GC responsiveness is deter-
mined by changes in clinical symptoms or disease activity
scores specific to the condition, which can take several
days to respond. For example, in patients with acute se-
vere alcoholic hepatitis GC response is determined at day
7 of treatment according to the Lille score [21]. Although
the BLISS assay represents a significant improvement in
the speed of determining clinical GC responsiveness, re-
sults still take a little over 48 h to obtain. This may be rele-
vant in certain conditions in which urgent GC treatment
cannot be delayed (e.g. acute severe ulcerative colitis or
acute life-threatening asthma). However, harm to the
patient from a short period of GC treatment is unlikely
and the BLISS assay will still have clinical utility to guide
subsequent patient management such as escalating ther-
apy in GC resistant patients.
Alternative methods have been reported to measure
cell proliferation by BrdU incorporation including
chemiluminescence and flow cytometry [17, 22]. The
chemiluminescence method is similar to the colorimet-
ric assay but uses a different substrate with 2 compo-
nents and requires a luminometer with photomultiplier
to detect light emission. Our proposed protocol uses a
premixed substrate and ELISA plate reader to measure
wavelength absorbance, making it marginally easier to
apply. Flow cytometry methods for BrdU measurement
allow quantification at a single cell level. However, flow
Table 1 Contingency table comparing classification of GC sensitive
(GC-S) and resistant (GC-R) subjects by DILPA and BLISS assays
DILPA
GC-R (Imax < 60%) GC-S Imax > 60%)
BLISS GC-R (Imax < 39%) 57 10
GC-S (Imax > 39%) 12 22
Sensitivity: 83% (95% confidence interval 71–90%)
Specificity: 69% (50–83%)
Positive Predictive Value: 85% (74–92%)
Negative Predictive Value: 65% (46–80%)
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cytometry requires the appropriate expertise and equip-
ment and may struggle with high throughput, limiting its
generalizability and translation into clinical laboratories.
The colorimetric assay we describe here is therefore the
most streamlined and easily accessible technique to meas-
ure cell proliferation.
Conclusions
In summary, we have reported the validation of a simple
novel bioassay with a standardized laboratory protocol
which accurately measures GC sensitivity. This has broad
translational implications and could be applied to many
inflammatory diseases to guide clinical management of
individual patients, ensuring that GC responsive patients
are correctly treated with GCs while reducing unnecessary
exposure to GCs and accelerating the appropriate escal-
ation of treatment of GC resistant patients. Further
validation in a clinical context is ongoing.
Additional file
Additional file 1: BLISS correlates with clinical GC sensitivity in patients
with acute severe alcoholic hepatitis. Preliminary data in 10 patients with
acute severe alcoholic hepatitis demonstrates significant correlation with
the Lille score (based on clinical and biochemical parameters after 7 days
of GC treatment). Lille scores range from 0 to 1 with higher Lille scores
associated with greater clinical GC resistance. Correlation coefficient = −0.74;
p = 0.02 (DOCX 14 kb)
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